Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
22
research findingsWording
Definitive
How definitive the wording is.Announced details
SMART TOUCH
Applicable field (uses covered by this announcement)
Contact lens safety and comfortMyopia progression control (orthokeratology)Contact lens material designDry eyeTear filmVisual function
Relationship between the counterparty and the company
Menicon Co.,Ltd.7780
Relationship with the Company
The company states that it has collaborated with clinical settings and research institutions in Japan and overseas, but the specific counterparties are unknown.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Source (materials cited by the company)
BCLA Asia 2026 and the 68th Annual Meeting of the Japanese Contact Lens Society
| Item | Details |
|---|---|
| Names of Products / Services Covered | SMART TOUCH |
| Relationship with the Company | The company states that it has collaborated with clinical settings and research institutions in Japan and overseas, but the specific counterparties are unknown. |
| Applicable area | Contact lens safety and comfort, Myopia progression control (orthokeratology), Contact lens material design, Dry eye, Tear film, Visual function |
| Source | BCLA Asia 2026 and the 68th Annual Meeting of the Japanese Contact Lens Society |
Items this document does not state (14)
CounterpartyCounterparty overviewContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To demonstrate its focus on providing evidence-based value through academic presentations and its collaboration with clinical settings and research institutions in Japan and overseas.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.